#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC

Corbus Pharmaceuticals reported encouraging early-stage results for its Nectin-4 targeting ADC in various types of cancer, but a lack of response in certain patients caused shares to slide. The biotech’s CRB-701 is given once every ...